FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

The U.S. Food and Drug Administration (FDA) recently approved belumosudil (Rezurock) a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic GvHD after failure of at least two prior lines of systemic therapy based on the results of Study KD025-213. Additional study is warranted to confirm safety in long-term use.